



IBA releases the second version of myQA®: Global QA Platform Further enhancing user connectivity and benchmarking via the Cloud

Extending the frontiers in highly efficient and effective QA workflows

Schwarzenbruck, Germany, September 30, 2015 – IBA (Ion Beam Applications S.A.), the global high-tech leader in the next generation of proton therapy solutions and radiation therapy dosimetry for the treatment of cancer, announces the second release of the new global quality assurance platform: **myQA®**. myQA is a unique platform that connects QA applications, people, and know-how through a Central Database and the Cloud. It offers full support to its users throughout the entire QA workflow, and provides access to all software modules and data from one intuitive interface.

*“It has been a remarkable journey thus far and we are proud to offer our customers the second release in only six months. Our goal is to continuously advance and upgrade myQA to the needs of our users and the demands of the market. IBA takes pride in assisting our customers to not only stay compliant, but also giving them the highest level of quality and efficiency in their QA. By communicating our continual growth model and benefits given through **myQA Coverage**, I trust that our customers have recognized our dedication to this goal. With upcoming installments already in the works, we are extremely excited to continue on this myQA journey!”* **says Bruno Marchand, Vice President of Research and Development at IBA Dosimetry.**

Since the initial release of myQA in March of this year, it has gained tremendous recognition, enthusiasm, and support from the radiation therapy community. Being the first and only of its kind; myQA is extending the frontiers in highly efficient and effective QA workflows. With the release of the highly anticipated myQA Cloud, the Support Portal, an even more advanced patient dashboard within myQA Cockpit, and much more, the evolution of myQA is proving its commitment to providing users with the latest and most advanced QA solution.

myQA Cloud offers users the valuable opportunity to anonymously benchmark their QA data and connect with users from around the world. This online tool not only contributes to best practice checks, but also gives its users full trust in their results. With the upgrade of **myQA Cockpit**, users are able to better track, review, and maintain their patient QA data on one interface. This new addition allows users to comfortably monitor their patient and machine QA data in one place and on any web-accessible device. myQA Cockpit is the gift of ultimate mobility and convenience.

“We at IBA always strive to provide the best services in the industry to our customers. To continue in this direction, myQA users now receive the extraordinary benefits of myQA Coverage,” **says Christian Kling, Vice President of Logistics and Services at IBA Dosimetry.** This includes a 24/7 hotline to speak directly with our professionally trained service staff as well as the newly released online Support Portal. This incredible tool has also been integrated into the myQA Platform for fast and convenient access. IBA’s Support Portal takes a great leap forward in helping our customers with all of their dosimetry questions – 24 hours a day, 7 days a week. We have already received a great deal of positive feedback from customers all over the world, as well as useful input that drives us to further

Press Release |



develop and continuously improve our customer service. I'm looking forward to the exciting new functionalities that each future implementation and release will offer."

[Learn more about myQA here.](#)

About IBA

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The Company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US and to the emerging markets. IBA is listed on the pan-European stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB) and more information can be found at: www.iba-worldwide.com

Media Contact:

Jacqueline McMahon
IBA Dosimetry GmbH
Bahnhofstr. 5
90592 Schwarzenbruck, Germany
Tel: +49 9128 607 0
jacqueline.mcmahon@iba-group.com
www.iba-dosimetry.com